Eli Lilly (NYSE: LLY) Reports Q2 2026 Earnings Wednesday August 5 With Revenue of $23 Billion (+48% Year-Over-Year), Full-Year 2026 Revenue Guidance Raised to $85-87 Billion From Prior $82-85 Billion; Mounjaro (Tirzepatide) Type 2 Diabetes Revenue Rose 91% to $9.9 Billion ($4.8B US + $5.2B International), Zepbound (Tirzepatide) Obesity Revenue Reached $4.9 Billion US (+44% YoY on Strong Prescription Volume More Than Offsetting Price Declines), Foundayo (Orforglipron) Generated $98 Million in Its First Fully Operational Commercial Quarter Since the April 2026 FDA Approval; Combined Mounjaro + Zepbound Franchise Reached $14.9 Billion for the Quarter, and LLY Shares Rose Approximately 4% Intraday
Eli Lilly (NYSE: LLY) reported Q2 2026 earnings Wednesday August 5, 2026 with revenue of $23 billion (+48% year-over-year), well ahead of analyst consensus of $20.5 billion. Full-year 2026 revenue guidance was raised to $85-87 billion from the prior $82-85 billion range. Mounjaro (tirzepatide for type 2 diabetes) revenue rose 91% to $9.9 billion, split $4.8 billion US and $5.2 billion international, with the international majority driven by aggregate international Mounjaro market share now above 50% per prior Lilly executive commentary. Zepbound (tirzepatide for obesity) delivered $4.9 billion in US revenue (+44% year-over-year), with strong prescription-volume growth more than offsetting the low-to-mid-teens price erosion Lilly had guided to for FY26. Foundayo (orforglipron, the first oral small-molecule GLP-1 receptor agonist approved by FDA in April 2026) generated $98 million in its first fully operational commercial quarter, providing the first commercial-earnings-line view of the oral small-molecule GLP-1 category. Combined Mounjaro + Zepbound franchise revenue reached $14.9 billion, representing approximately 65% of total Lilly revenue for the quarter. LLY shares rose approximately 4% intraday on the earnings and guidance beat. Analyst commentary flagged the substantial widening of the Lilly-Novo obesity franchise gap.